High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia (Q80313380)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16990760%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

title

High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16990760%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

main subject

lymphoblastic leukemia

1 reference

1 reference

T V Ch Skärby

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16990760%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

H Anderson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16990760%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

J Heldrup

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16990760%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

J A Kanerva

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16990760%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

H Seidel

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16990760%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

K Schmiegelow

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16990760%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Nordic Society of Paediatric Haematology and Oncology (NOPHO)

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16990760%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

publication date

21 September 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16990760%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16990760%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16990760%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16990760%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

page(s)

1955-1962

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16990760%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404404

30 December 2019

exact match

0 references

cites work

High-dose methotrexate: a critical reappraisal

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404404

7 January 2021

Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404404

7 January 2021

Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in children

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404404

7 January 2021

Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404404

7 January 2021

On the prognostic value of systemic methotrexate clearance in childhood acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404404

7 January 2021

Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404404

7 January 2021

Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404404

7 January 2021

Mechanism of leucovorin reversal of methotrexate cytotoxicity in human MCF-7 breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404404

7 January 2021

Reversal of Methotrexate Cytotoxicity to Human Bone Marrow Cells and Leukemic K562 Cells by Leucovorin: Methotrexate Polyglutamates Formation as a Possible Important Factor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404404

7 January 2021

[The effect of methotrexate pharmacokinetics and of leucovorin rescue on the prognosis of osteosarcoma]

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404404

7 January 2021

How much is too much? Folinic acid rescue dose in children with acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404404

7 January 2021

Pretreatment plasma folate modulates the pharmacodynamic effect of high-dose methotrexate in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma: "folate overrescue" concept revisited

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404404

7 January 2021

Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404404

7 January 2021

Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404404

7 January 2021

Dose reduction of coadministered 6-mercaptopurine decreases myelotoxicity following high-dose methotrexate in childhood leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404404

7 January 2021

Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404404

7 January 2021

Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404404

7 January 2021

The association of the TEL-AML1 chromosomal translocation with the accumulation of methotrexate polyglutamates in lymphoblasts and with ploidy in childhood B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404404

7 January 2021

Accumulation of methotrexate polyglutamates, ploidy and trisomies of both chromosomes 4 and 10 in lymphoblasts from children with B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404404

7 January 2021

Defining the appropriate dosage of folinic acid after high-dose methotrexate for childhood acute lymphatic leukemia that will prevent neurotoxicity without rescuing malignant cells in the central nervous system

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404404

7 January 2021

Ratio of methotrexate to folate uptake by lymphoblasts in children with B-lineage acute lymphoblastic leukemia: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404404

7 January 2021